Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een DNAJB1-PRKACA-fusiekinase-peptidevaccin gecombineerd met glutamine-antagonist DRP-104, nivolumab en ipilimumab bij patiënten met gevorderd fibrolamellair carcinoom (FLC)

Een fase 1b-studie van een DNAJB1-PRKACA-fusiekinasepeptidevaccin gecombineerd met glutamine-antagonist DRP-104, nivolumab en ipilimumab voor patiënten met gevorderd fibrolamellair hepatocellulair carcinoom (FLC)

The purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, assessed by RECIST 1.1). Secondary objectives include progression-free survival (PFS) and overall survival (OS).

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

27

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21231
        • Werving
        • Johns Hopkins SKCCC
        • Contact:
        • Hoofdonderzoeker:
          • Marina Baretti, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

12 jaar en ouder (Kind, Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Must have histologically confirmed FLC that is metastatic or unresectable.
  • Presence of DNAJB1-PRKACA fusion transcript, assessed by RNA-sequencing, DNA-sequencing, or in situ hybridization in the archival tissue.
  • Must have demonstrated radiographic progression on prior or current immunotherapy.
  • Age ≥ 12 years.
  • Patients < 18 years old must have a body weight ≥ 40 kg.
  • ECOG (Eastern Cooperative Oncology Group) performance status of ≤2
  • Patients must have adequate organ and marrow function defined by study-specified laboratory tests.
  • Patients must have adequate kidney and liver function defined by study-specified laboratory tests.
  • Must have measurable disease per RECIST 1.1
  • Willingness to provide tissue and blood samples for mandatory translational research.
  • Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test.
  • For both Women and Men, must use acceptable form of birth control while on study.
  • Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

  • Patients with a history of prior treatment with checkpoint inhibitors, such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, anti-CTLA-4, or anti-LAG-3 antibodies.

  • Must have had chemotherapy or other systemic therapy or radiotherapy, as follows:

    • Patients who have had chemotherapy, biological cancer therapy, or radiation 14 days prior to the first dose of study drug.
    • Patients who have had surgery within 28 days of dosing of investigational agent, excluding minor procedures.
    • Patients who have received other approved or investigational agents or device within 28 days of the first dose of study drug.
  • Patients who have not recovered from acute adverse events to grade ≤1 or baseline due to agents administered, with exception of grade 2 fatigue, rash, and endocrinopathy successfully managed hormone replacement therapy, or alopecia or stable neuropathy, unless approved by the IND Sponsor.

  • Patients who have received any non-oncology live vaccine therapy used for prevention of infectious diseases within 28 days of study treatment.

  • Known sensitivity to or history of allergic reactions attributed to compounds of similar chemical or biologic composition of polyinosinic-polycytidylic acid (Poly-ICLC) and/or DRP-104 and/or nivolumab and/or ipilimumab.

  • History of severe hypersensitivity reaction to any monoclonal antibody.

  • Has an active autoimmune disease.

  • Prior allogeneic stem cell transplantation or organ transplantation.

  • Has a diagnosis of immunodeficiency.

  • Systemic corticosteroids at immunosuppressive doses.

  • Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.

  • Has a pulse oximetry of <92% on room air or is on supplemental home oxygen.

  • Active or untreated brain metastases or leptomeningeal metastases.

  • Uncontrolled intercurrent active medical and/or psychiatric illness/social psychosocial problems that that would limit compliance with study requirements.

  • Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.

  • Pregnant or breastfeeding.

  • Has a known history of Human Immunodeficiency Virus (HIV)/AIDS.

  • Has active hepatitis B. Patients with chronic or acute HBV infection.

  • Have had evidence of active or acute diverticulitis, intra-abdominal abscess, or GI obstruction which are known risk factors for bowel perforation should be evaluated for the potential need for additional treatment before coming on study.

  • Unwilling or unable to follow the study schedule for any reason.

  • Patient is at the time of signing informed consent a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).

  • Evidence of clinical ascites.

  • Patients with QTc prolongation > 470 ms according to Fridericia formula.

  • Patients receiving potent inducers of CYP 3A4/5 (including but not limited to apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin and St. John's Wort) who cannot safely discontinue drug at least 14 days prior to Cycle 1 Day 1.

  • Have had an allergen hyposensitization therapy within 2 weeks prior to initiation of study treatment.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Arm A - DNAJB1-PRKACA-peptidevaccin met poly-ICLC-adjuvans, DRP-104, Nivolumab en Ipilimumab
  1. Patients will receive treatment on Day 1, 8 and 15 of cycle 1 and on Day 1 of cycle 2, 3, and 4 (Prime Phase). Boost vaccinations will be administered every 3 cycles beginning from C5D1.
  2. Drug: 0.3 mg DNAJB1-PRKACA peptide vaccine + 0.5 mg Poly-ICLC
Andere namen:
  • Hiltonol® (poly-ICLC)
  1. Patients will receive treatment on Day 1, 4, 8, 11, 15, and 18 of cycle 1-4 (Prime Phase) then on Days 1, 4, 8, 11, 15, 18, 22 and 25 of each cycle starting on Day 1 of Cycle 5 (Boost/maintenance Phase). DRP-104 will be administered as a subcutaneous injection twice a week (BIW) on a continuous schedule for up to two years.
  2. Drug: 145 mg
  1. Patients will receive treatment on Day 1 of each Cycle. Nivolumab 3mg/kg will be administered every 3 weeks as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 1-4 (Prime Phase). Nivolumab infusions will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 5 (Boost/maintenance).
  2. Drug: 3mg/kg and 480mg IV
Andere namen:
  • OPDIVO
  1. Patients will receive treatment on Day 1 of Cycle 1-4 (Prime Phase). Ipilimumab (1 mg/kg) will be administered. Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10/+15min).
  2. Drug: 1mg/kg IV
Andere namen:
  • YERVOY®

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of participants experiencing grade 3 or above drug-related toxicities
Tijdsspanne: 4 years

When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v6.0) will be counted only once for a given subject.

4 years
Objective response rate (ORR) using immune Response Evaluation Criteria for Solid Tumors (RECIST 1.1)
Tijdsspanne: 4 years

ORR is defined as the percentage of patients achieving a complete response (CR) or partial response (PR) to DRP-104 in combination with DRP-104, Nivolumab and Ipilimumab, based on the immune Response Evaluation Criteria in Solid Tumors (RECIST 1.1) at any time during the study. CR = disappearance of all target lesions, PR is =>30percent decrease in sum of diameters of target lesions, progressive disease (PD) is >20percent increase in sum of diameters of target lesions, stable disease (SD) is <30percent decrease or <20percent increase in sum of diameters of target lesions.

4 years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Progression-free Survival (PFS) number of months according to RECIST (1.1) criteria.
Tijdsspanne: 4 years

PFS is defined as the number of months from the date of first treatment to disease progression (progressive disease [PD] or relapse from complete response [CR] as assessed using RECIST 1.1 criteria) or death due to any cause. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is >20% increase in sum of diameters of target lesions, Stable Disease (SD) is <30% decrease or <20% increase in sum of diameters of target lesions.

4 years
Overall survival (OS) of patients treated with study drug combination
Tijdsspanne: 4 years

OS is defined as the number of months from the first dose of study treatment to death from any cause. (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.

4 years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Marina Baretti, MD, SKCCC • Johns Hopkins Medical Institution

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

28 oktober 2026

Primaire voltooiing (Geschat)

1 oktober 2030

Studie voltooiing (Geschat)

1 oktober 2030

Studieregistratiedata

Eerst ingediend

18 februari 2026

Eerst ingediend dat voldeed aan de QC-criteria

18 februari 2026

Eerst geplaatst (Werkelijk)

24 februari 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

30 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

29 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren